Amgen's Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors

Amgen Inc.'s well-designed GAUSS-3 study shows a role of its PCSK9 inhibitor Repatha in patients who truly can't tolerate statins, but how this translates into real-world utilization in the highly cost-conscious cardiology space remains to be seen.